Expanded antibody-based clues to TB risk in people with HIV
Official title: Expanded evaluation of the role of antibody-dependent innate effector function in TB disease progression in HIV co-infected individuals
Funded at University of Colorado Denver · NIH-11617206 · Data updated 2026-11-12
A clinician-scientist seeks to understand how antibodies in people with HIV may drive the progression from latent TB to active TB, with the goal of identifying clues that could guide future care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | September 12, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $194,400 |
| NIH project number | 7K08AI194971-02 |
| Project ID | NIH-11617206 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who are at risk for TB progression and can participate in antibody function studies.
✕Less likely to help
Patients without HIV or TB risk may not benefit from this specific immune-function research.
What this research studies
This program will explore how antibody Fc features and Fc-mediated functions are altered in HIV-positive individuals and how these changes relate to TB progression. The project plans to profile a broad set of antibody activities, especially those that activate neutrophils and other innate defenses, to see which features correlate with higher TB risk. It combines a five-year career development plan with translational laboratory work to link immune signals to TB outcomes in the HIV context. The findings could point to biomarkers or targets that help tailor TB prevention or treatment in people living with HIV.
Why it matters
Potential benefit: If successful, it could help identify immune markers that predict TB risk in HIV patients and suggest approaches to reduce that risk.
How similar studies have gone: Previous data show antibodies can influence TB outcomes in HIV-zero settings, and this work extends those ideas to HIV co-infection.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Bowman, Kathryn Anne — University of Colorado Denver
- Study coordinator: Bowman, Kathryn Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.